Claus Hanusch
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber K, Rachakonda S, Braun M, Huober J, Jank P, Sinn H, Zahm D, Felder B, Hanusch C, Teply-Szymanski J, Marme F, Fehm T, Thomalla J, Sinn B, Stiewe T, Marczyk M, Blohmer J, van Mackelenbergh M, Schem C, Staib P, Link T, Müller V, Stickeler E, Stover D, Solbach C, Metzger-Filho O, Jackisch C, Geyer C, Fasching P, Pusztai L, Nekljudova V, Untch M, Loibl S. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. Cell Rep Med 2024; 5:101825.
Nov 19, 2024Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.
Nov 19, 2024Cell Rep Med 2024; 5:101825
Denkert Carsten, Schneeweiss Andreas, Rey Julia, Karn Thomas, Hattesohl Akira, Weber Karsten E, Rachakonda Sivaramakrishna, Braun Michael, Huober Jens, Jank Paul, Sinn Hans-Peter, Zahm Dirk-Michael, Felder Bärbel, Hanusch Claus, Teply-Szymanski Julia, Marme Frederik, Fehm Tanja N, Thomalla Jörg, Sinn Bruno Valentin, Stiewe Thorsten, Marczyk Michal, Blohmer Jens-Uwe, van Mackelenbergh Marion T, Schem Christian, Staib Peter, Link Theresa, Müller Volkmar, Stickeler Elmar, Stover Daniel G, Solbach Christine, Metzger-Filho Otto, Jackisch Christian, Geyer Charles E, Fasching Peter Andreas, Pusztai Lajos, Nekljudova Valentina, Untch Michael, Loibl Sibylle
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm D, Hanusch C, Solbach C, Heinrich G, Hartkopf A, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). ESMO Open 2024; 9:103009.
Apr 24, 2024Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Apr 24, 2024ESMO Open 2024; 9:103009
Meyer-Wilmes P, Huober Jens, Untch Michael, Blohmer J-U, Janni Wolfgang, Denkert Carsten, Klare Peter, Link Theresa, Rhiem Kerstin, Bayer C, Reinisch Mattea, Bjelic-Radisic Vesna, Zahm Dirk Michael, Hanusch Claus, Solbach Christine, Heinrich Georg, Hartkopf Andreas D, Schneeweiss Andreas, Fasching Peter Andreas, Filmann N, Nekljudova Valentina, Holtschmidt J, Stickeler Elmar, Loibl Sibylle
Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clin Transl Med 2024; 14:e1617.
Apr 1, 2024Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Apr 1, 2024Clin Transl Med 2024; 14:e1617
Massa Chiara, Karn Thomas, Weber Karsten E, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion T, Thomalla Jörg, Marme Frederik, Huober Jens, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter Andreas, Untch Michael, Loibl Sibylle, Denkert Carsten, Seliger Barbara
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, Stötzer O, Fasching P, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn B, Nekljudova V, Loibl S, Denkert C. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial. Clin Cancer Res 2023
Sep 19, 2023RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
Sep 19, 2023Clin Cancer Res 2023
Link Theresa, Blohmer Jens-Uwe, Schmitt Wolfgang Daniel, Kuhlmann Jan Dominik, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter Andreas, Thill Marc, Reinisch Mattea, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, Huober Jens, Jackisch Christian, Rhiem Kerstin, Hanusch Claus, Sinn Bruno Valentin, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, Tesch H, Hanusch C, Salat C, Rhiem K, Solbach C, Fasching P, Jackisch C, Reinisch M, Lederer B, Mehta K, Link T, Nekljudova V, Loibl S, Untch M. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy. NPJ Breast Cancer 2023; 9:23.
Apr 7, 2023Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy.
Apr 7, 2023NPJ Breast Cancer 2023; 9:23
Huober Jens, van Mackelenbergh Marion T, Schneeweiss Andreas, Seither Fenja, Blohmer Jens-Uwe, Denkert Carsten, Tesch Hans, Hanusch Claus, Salat Christoph, Rhiem Kerstin, Solbach Christine, Fasching Peter Andreas, Jackisch Christian, Reinisch Mattea, Lederer Bianca, Mehta Keyur M, Link Theresa, Nekljudova Valentina, Loibl Sibylle, Untch Michael
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel) 2022; 14
Jan 20, 2022Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
Jan 20, 2022Cancers (Basel) 2022; 14
Gerber Bernd, Untch Michael, Kast Karin, Jackisch Christian, Thomalla Jörg, Seither Fenja, Blohmer Jens-Uwe, Rhiem Kerstin, Fasching Peter A, Nekljudova Valentina, Loibl Sibylle, Hahn Markus, Klare Peter, Ataseven Beyhan, Schneeweiss Andreas, Möbus Volker, Golatta Michael, Tesch Hans, Krug David, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Heil Jörg, Huober Jens, Kühn Thorsten
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
Jan 1, 2022Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Jan 1, 2022JAMA Oncol 2022; 8:1010-1018
Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 2021
Nov 17, 2021Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Nov 17, 2021Eur J Cancer 2021
Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübbe K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22:1151-1161.
Jul 9, 2021Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Jul 9, 2021Lancet Oncol 2021; 22:1151-1161
Denkert Carsten, Huober Jens, Rhiem Kerstin, Marme Frederik, Reimer Toralf, Schmidt Marcus, Sinn Bruno V, Janni Wolfgang, Stickeler Elmar, Michel Laura, Stötzer Oliver, Hahnen Eric, Furlanetto Jenny, Seiler Sabine, Nekljudova Valentina, Untch Michael, Solbach Christine, Lübbe Kristina, Seither Fenja, Schneeweiss Andreas, Link Theresa, Blohmer Jens-Uwe, Just Marianne, Wimberger Pauline, Forberger Almuth, Tesch Hans, Jackisch Christian, Schmatloch Sabine, Reinisch Mattea, Solomayer Erich F, Schmitt Wolfgang D, Hanusch Claus, Fasching Peter A, Loibl Sibylle
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Marme F, Loibl S, Lederer B, Tesch H, Hanusch C, Denkert C, Rey J, Rhiem K, Link T, Nekljudova V, Jackisch C, Fasching P, Huober J, Blohmer J, Schneeweiss A, Michel L, Solbach C, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 153:203-212.
Jun 26, 2021Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Jun 26, 2021Eur J Cancer 2021; 153:203-212
Marme Frederik, Loibl Sibylle, Lederer Bianca, Tesch Hans, Hanusch Claus, Denkert Carsten, Rey Julia, Rhiem Kerstin, Link Theresa, Nekljudova Valentina, Jackisch Christian, Fasching Peter A, Huober Jens, Blohmer Jens-Uwe, Schneeweiss Andreas, Michel Laura, Solbach Christine, Untch Michael
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148:159-170.
Mar 18, 2021Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Mar 18, 2021Eur J Cancer 2021; 148:159-170
Villegas Sonia L, Huober Jens, Lederer Bianca, van Mackelenbergh Marion, Tesch Hans, Jackisch Christian, Rezai Mahdi, Sinn Peter, Sinn Bruno V, Hackmann John, Kiechle Marion, Schneeweiss Andreas, Weichert Wilko, Denkert Carsten, Schmitt Wolfgang D, Hanusch Claus, Nekljudova Valentina, Pfarr Nicole, Engel Jutta, Untch Michael, Schrodi Simone, Holms Frank, Ulmer Hans U, Fasching Peter A, Weber Karsten E, Albig Christian, Heinrichs Clemens, Marme Frederik, Hartmann Arndt, Loibl Sibylle
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy
Furlanetto J, Lederer B, Gerber B, Zahm D, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Couch F, Schmutzler R, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J, Lübbe K, Untch M, Salat C, Huober J, Klare P, Fasching P. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2021; 145:44-52.
Jan 7, 2021Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy
Jan 7, 2021Eur J Cancer 2021; 145:44-52
Furlanetto Jenny, Lederer Bianca, Gerber Bernd, Zahm Dirk-Michael, Bauerfeind Ingo, Nekljudova Valentina, Hanusch Claus, Jackisch Christian, Link Theresa, Hahnen Eric, Loibl Sibylle, Couch Fergus J, Schmutzler Rita, Möbus Volker, Schneeweiss Andreas, Rhiem Kerstin, Tesch Hans, Blohmer Jens-Uwe, Lübbe Kristina, Untch Michael, Salat Christoph, Huober Jens, Klare Peter, Fasching Peter A
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
Werutsky G, Nekljudova V, Vladimirova V, Kühn T, Rhiem K, Huober J, Krug D, Link T, Schneeweiss A, Gerber B, Jackisch C, Tesch H, Denkert C, Seiler S, Blohmer J, Fasching P, Hanusch C, Untch M, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer 2020; 130:92-101.
Mar 13, 2020Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
Mar 13, 2020Eur J Cancer 2020; 130:92-101
Werutsky Gustavo, Nekljudova Valentina, Vladimirova Valentina, Kühn Thorsten, Rhiem Kerstin, Huober Jens, Krug David, Link Theresa, Schneeweiss Andreas, Gerber Bernd, Jackisch Christian, Tesch Hans, Denkert Carsten, Seiler Sabine, Blohmer Jens-Uwe, Fasching Peter A, Hanusch Claus, Untch Michael, Loibl Sibylle
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res 2020; 26:1896-1904.
Jan 13, 2020A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Jan 13, 2020Clin Cancer Res 2020; 26:1896-1904
Karn Thomas, Schem Christian, Young Brandon M, Hanusch Claus, Stickeler Elmar, Huober Jens, van Mackelenbergh Marion, Leyland-Jones Brian, Fehm Tanja, Nekljudova Valentina, Untch Michael, Gerber Bernd, Holtrich Uwe, Müller Volkmar, Meissner Tobias, Weber Karsten E, Solbach Christine, Denkert Carsten, Engels Knut, Fasching Peter A, Sinn Bruno V, Schrader Iris, Budczies Jan, Marme Frederik, Loibl Sibylle
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Massa C, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Weber K, Huober J, Marme F, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer 2020; 8
Jan 1, 2020Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Jan 1, 2020J Immunother Cancer 2020; 8
Massa Chiara, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter A, Untch Michael, Loibl Sibylle, Weber Karsten, Huober Jens, Marme Frederik, Karn Thomas, Denkert Carsten, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion, Thomalla Jörg, Seliger Barbara
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
Krug D, Huober J, Jackisch C, Kümmel S, Paepke S, Schem C, Schneeweiss A, Untch M, Debus J, von Minckwitz G, Kühn T, Hilfrich J, Heil J, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer J, Costa S, Denkert C, Ditsch N, Gerber B, Hanusch C, Loibl S. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Ann Surg Oncol 2019; 26:3892-3901.
Jul 26, 2019Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
Jul 26, 2019Ann Surg Oncol 2019; 26:3892-3901
Krug David, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Schem Christian, Schneeweiss Andreas, Untch Michael, Debus Jürgen, von Minckwitz Gunter, Kühn Thorsten, Hilfrich Jörn, Heil Joerg, Lederer Bianca, Seither Fenja, Nekljudova Valentina, Ataseven Beyhan, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Ditsch Nina, Gerber Bernd, Hanusch Claus, Loibl Sibylle
Fatal events during clinical trials: an evaluation of deaths during breast cancer studies
Furlanetto J, Mehta K, Nekljudova V, Untch M, Thomssen C, Hanusch C, Lück H, Nitz U, Bauerfeind I, Gerber B, Fasching P, Huober J, Schneeweiss A, Möbus V, Lederer B, von Minckwitz G, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer 2019; 26:826-834.
Jun 28, 2019Fatal events during clinical trials: an evaluation of deaths during breast cancer studies
Jun 28, 2019Breast Cancer 2019; 26:826-834
Furlanetto Jenny, Mehta Keyur, Nekljudova Valentina, Untch Michael, Thomssen Christoph, Hanusch Claus, Lück Hans-Joachim, Nitz Ulrike, Bauerfeind Ingo, Gerber Bernd, Fasching Peter A, Huober Jens, Schneeweiss Andreas, Möbus Volker, Lederer Bianca, von Minckwitz Gunter, Loibl Sibylle
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Untch M, Hackmann J, Blohmer J, Rhiem K, Schmitt W, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Hanusch C, Just M, Fasching P, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol 2019; 37:2226-2234.
May 13, 2019NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
May 13, 2019J Clin Oncol 2019; 37:2226-2234
Untch Michael, Hackmann John, Blohmer Jens-Uwe, Rhiem Kerstin, Schmitt Wolfgang D, Furlanetto Jenny, Gerber Bernd, Huober Jens, Nekljudova Valentina, von Minckwitz Gunter, Hanusch Claus, Just Marianne, Fasching Peter A, Jackisch Christian, Schneeweiss Andreas, Schmatloch Sabine, Aktas Bahriye, Denkert Carsten, Schem Christian, Wiebringhaus Hermann, Kümmel Sherko, Warm Mathias, Loibl Sibylle
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Res 2019; 21:60.
May 10, 2019Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
May 10, 2019Breast Cancer Res 2019; 21:60
Laakmann Elena, Ingold-Heppner Barbara, Huober Jens, Hanusch Claus, Jackisch Christian, Reinisch Mattea, Untch Michael, von Minckwitz Gunter, Nekljudova Valentina, Müller Volkmar, Blohmer Jens-Uwe, Zahm Dirk-Michael, Witzel Isabell, Fasching Peter A, Rezai Mahdi, Schem Christian, Solbach Christine, Tesch Hans, Klare Peter, Schneeweiss Andreas, Salat Christoph, Loibl Sibylle
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Schneeweiss A, Ingold-Heppner B, Blohmer J, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, von Minckwitz G, Thomalla J, Jackisch C, Kast K, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer 2018; 106:181-192.
Dec 5, 2018Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Dec 5, 2018Eur J Cancer 2018; 106:181-192
Schneeweiss Andreas, Ingold-Heppner Barbara, Blohmer Jens-Uwe, Rezai Mahdi, Frank Matthias, Engels Knut, Rhiem Kerstin, Fasching Peter Andreas, Nekljudova Valentina, von Minckwitz Gunter, Thomalla Jörg, Jackisch Christian, Kast Karin, Möbus Volker, Tesch Hans, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Huober Jens, Klare Peter, Kümmel Sherko, Untch Michael, Loibl Sibylle